Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 in Advanced HCC
NCT07422753Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Started Mar 2026; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07422753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422753.